APA
Maughan B. L., Suzman D. L., Luber B., Wang H., Glavaris S., Hughes R., Sullivan R., Harb R., Boudadi K., Paller C., Eisenberger M., Demarzo A., Ross A. & Antonarakis E. S. (20170606). Pharmacodynamic study of the oral hedgehog pathway inhibitor, vismodegib, in patients with metastatic castration-resistant prostate cancer. : Cancer chemotherapy and pharmacology.
Chicago
Maughan Benjamin L, Suzman Daniel L, Luber Brandon, Wang Hao, Glavaris Stephanie, Hughes Robert, Sullivan Rana, Harb Rana, Boudadi Karim, Paller Channing, Eisenberger Mario, Demarzo Angelo, Ross Ashely and Antonarakis Emmanuel S. 20170606. Pharmacodynamic study of the oral hedgehog pathway inhibitor, vismodegib, in patients with metastatic castration-resistant prostate cancer. : Cancer chemotherapy and pharmacology.
Harvard
Maughan B. L., Suzman D. L., Luber B., Wang H., Glavaris S., Hughes R., Sullivan R., Harb R., Boudadi K., Paller C., Eisenberger M., Demarzo A., Ross A. and Antonarakis E. S. (20170606). Pharmacodynamic study of the oral hedgehog pathway inhibitor, vismodegib, in patients with metastatic castration-resistant prostate cancer. : Cancer chemotherapy and pharmacology.
MLA
Maughan Benjamin L, Suzman Daniel L, Luber Brandon, Wang Hao, Glavaris Stephanie, Hughes Robert, Sullivan Rana, Harb Rana, Boudadi Karim, Paller Channing, Eisenberger Mario, Demarzo Angelo, Ross Ashely and Antonarakis Emmanuel S. Pharmacodynamic study of the oral hedgehog pathway inhibitor, vismodegib, in patients with metastatic castration-resistant prostate cancer. : Cancer chemotherapy and pharmacology. 20170606.